Pelareorep + atezolizumab and chemotherapy in third-line (3L) metastatic colorectal cancer (mCRC) patients – Interim results from the GOBLET study

Ungerechts, Guy et al. Previously presented at ESMO Congress 2023, Oct. 22, 2023